Staphylococcus aureus can cause a variety of acute and chronic diseases. The ability of S. aureus to cause persistent infections has been linked to its ability to evade or inactivate host immune responses. We have identified a secreted 19-kDa protein produced by S. aureus that binds to the complement protein C3. Nterminal sequencing of this protein identified it as the extracellular fibrinogen-binding protein (Efb). In this study, we demonstrate that Efb can bind to the a-chain of C3 and inhibit both the classical and alternative pathways of complement activation. In addition, we show that Efb can inhibit complement-mediated opsonophagocytosis in a dose-dependent manner and that Efb inhibits complement activity by blocking deposition of C3 or by preventing further complement activation beyond C3b. These data suggest that Efb is a virulence factor involved in facilitating persistent S. aureus infections by interfering with complement activity in vivo.
Staphylococcus aureus can cause a variety of acute and chronic diseases. The ability of S. aureus to cause persistent infections has been linked to its ability to evade or inactivate host immune responses. We have identified a secreted 19-kDa protein produced by S. aureus that binds to the complement protein C3. Nterminal sequencing of this protein identified it as the extracellular fibrinogen-binding protein (Efb). In this study, we demonstrate that Efb can bind to the a-chain of C3 and inhibit both the classical and alternative pathways of complement activation. In addition, we show that Efb can inhibit complement-mediated opsonophagocytosis in a dose-dependent manner and that Efb inhibits complement activity by blocking deposition of C3 or by preventing further complement activation beyond C3b. These data suggest that Efb is a virulence factor involved in facilitating persistent S. aureus infections by interfering with complement activity in vivo.
Staphylococcus aureus colonizes the skin and anterior nares of 20% of healthy humans without causing disease or discernible clinical symptoms [1, 2] . However, S. aureus remains one of the most common causes of infections in the industrialized world, and the emergence of antibiotic-resistant S. aureus strains poses severe health threats to hospitals and communities [1, 3] . Furthermore, the broad spectrum of diseases that can result from S. aureus infections (e.g., skin infections, endocarditis, arthritis, osteomyelitis, or sepsis) are a reflection of this organism's capacity to not only colonize a variety of different tissues but to also circumvent a variety of immune surveillance systems, which results in the persistence of S. aureus in different environments within the host organism [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] .
Because pathogens associated with persistent infections must constantly avoid host immunity to survive, it is not surprising that these bacteria produce multiple microbial immunomodulatory molecules targeting the different host defense systems (innate and adaptive immunity) [12] . The complement system represents the most "primitive" line of defense against infectious agents. The importance of the complement system as a primary defense mechanism in vertebrates is mirrored by the fact that infectious agents-including bacteria, viruses, protozoans, helminths, and fungi-have developed strategies that interfere with, avoid, or manipulate complementsystem components [14] [15] [16] [17] . One of the critical components of the complement cascade is the complement protein C3. This protein not only plays a crucial role as an opsonin but also is the common link between the alternative, classical, and mannose-binding lectin (MBL) pathways of complement activation [17] .
S. aureus has been shown to activate all 3 pathways of the complement system (classical, alternative, and MBL) [18] [19] [20] [21] [22] . The activation of the complement pathway leads to the deposition of C3b on the surface of S. aureus, resulting in the opsonophagocytic killing of the bacteria. In a mouse model of S. aureus-induced septicemia and septic arthritis, mice that were complement depleted by treatment with cobra venom factor presented with significantly increased disease severity, suggesting a role for complement in controlling hematogenously acquired S. aureus infections [23] .
Considering the ability of S. aureus to cause persistent infections, it is likely that S. aureus can counter complement activity. C3 plays a central role in all 3 complement pathways and is therefore a potential target for inactivation by the pathogen. We initiated a search for an S. aureus C3-binding protein and have identified a secreted 19-kDa protein that can bind to C3 in a Western ligand blot assay. N-terminal sequencing identified this protein as the S. aureus extracellular fibrinogen-binding protein (Efb) [5, [24] [25] [26] [27] . Efb is a constitutively secreted protein that not only binds fibrinogen but also can interfere with platelet aggregation and is hypothesized to play a role in delaying wound healing [27] [28] [29] [30] . The present report supports a role for Efb as an inhibitor of complement activation and suggests that Efb may play a role as a virulence factor in persistent S. aureus infections.
MATERIALS AND METHODS
Cloning of the efb and sa1755 genes from S. aureus strain Newman. The efb and the sa1755 genes, excluding the 5 sequence encoding the signal peptide, were amplified by use of polymerase chain reaction (PCR), with S. aureus strain Newman DNA as a template. The following oligonucleotide primers were used: 5 -CGC GGA TCC CCA AGA GAA AAG AAA CCA GTG AGT A-3 (forward primer) and 5 -AAC TGC AGA GTT  TTA TTT AAC TAA TCC TTG-3 (reverse primer) and 5 -CGC  GGA TCC CCG TTT CCT ACA AAT GAA GAA-3 (forward  primer) and 5 -AAC TGC AGC TAG TAT GCA TAT TCA TTA-3 (reverse primer) (IDT) , for efb and sa1755, respectively. The resulting PCR amplifications were subsequently cloned by use of the TA Expression Kit into the pCRT7/NT-TOPO expression vector (both from Invitrogen) and were designated as pCRT7/ NT-Efb or pCRT7/NT-SA1755, respectively. Nucleotide sequencing of efb and sa1755 were performed by automated sequencing (Molecular Genetics Core Facility, University of Texas-Houston Medical School).
Expression and purification of recombinant proteins. The S. aureus proteins Efb, SA1755, and major histocompatibility complex analog protein (Map) 19 [12] and the Staphylococcus epidermidis fibrinogen-binding protein (SdrG) [31] were expressed as recombinant N-terminal His-tagged proteins, which allowed for purification using metal ion-chelating chromotography, as described elsewhere [12, 32] . Map19 and SdrG were expressed by use of the pQE30 (QIAGEN) expression vector in Escherichia coli (JM101; Stratagene), and Efb and SA1755 were expressed by use of the pCRT7/NT-TOPO (Invitrogen) expression vector in E. coli (BL21) harboring the corresponding plasmids. Proteins were expressed and purified as described elsewhere [32, 33] . Protein concentrations were determined by use of the bicinchoninic acid (BCA) protein assay (Pierce), and proteins were stored at Ϫ20ЊC until use.
Western ligand blotting. E. coli strain JM101, Staphylococcus carnosus strain TM300, and S. aureus strain Newman were grown under constant shaking conditions overnight at 37ЊC in 5 mL of Lennox broth (Sigma-Aldrich), as described elsewhere [12, 34] . Bacteria were washed in PBS, and total protein was quantified by use of BCA (Pierce). Bacteria (20 mg), S. aureus supernatants from overnight cultures (20 mL), recombinant proteins (4 mg each), C3b or C3 (2 mg) (Advanced Research Technologies), human fibrinogen (2 mg) [31] , or human serum (20 mL of a 1:20 dilution in PBS) (Diamedix) were subjected to SDS-PAGE and examined by staining with 0.05% Coomassie brilliant blue or were electrotransferred to a 0.45-mm Immobilon-P polyvinylidene fluoride (PVDF) membrane (Millipore), as described elsewhere [34] .
Membranes subjected to Western blot analysis were blocked overnight at 4ЊC in 5% nonfat dry milk in TBST (0.15 mol/L NaCl, 20 mmol/L Tris-HCl, and 0.05% Tween 20 [Sigma-Aldrich] [pH 7.4]), were probed accordingly, and then were developed with 10 mL of 1-Step nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate solution (Pierce). All incubations were performed in 15 mL of 1% TBST for 1 h at room temperature, with shaking, and membranes were washed in TBST between all steps. Labeling with digoxigenin was performed as described elsewhere, in accordance with the manufacturer's instructions [34] . N-terminal sequencing was performed at the Protein Chemistry Laboratory of Texas A&M University, College Station.
ELISA-type binding assays. Immulon-1 microtiter plate wells (Dynatech Laboratories) were coated with 0.25 mg of either C3b or fibrinogen in 50 mL of PBS for 2 h. The plates were washed and blocked with 200 mL of Super Block (Pierce) for 1 h. Recombinant proteins (0-20 mmol/L [at a final volume of 100 mL]/well) were added to the wells and incubated for 1 h. In the next step, 100 mL of anti-His antibodies (1:5000) were added and incubated for 1 h, followed by addition of 100 mL of goat anti-mouse alkaline phosphatase (AP)-conjugated antibodies (1:5000). Next, 100 mL of a 1 mg/mL Sigma 104 phosphatase substrate (Sigma) dissolved in 1 mol/L diethanolamine and 0.5 mmol/L MgCl 2 (pH 9.8) was added, and the plates were allowed to develop for 1 h. Plates were read at 405 nm by use of a microplate reader (Molecular Devices). Plates were washed between all steps, with PBS-0.05% Tween 20, and all incubations took place at 37ЊC. All dilutions were made using Super Block, unless otherwise specified.
Complement-activity assays. The EZ Complement CH50 clinical diagnostic assay kit (Diamedix) was used to evaluate the effects of recombinant Efb on activation of the classical pathway and was used as described by the manufacturer. In brief, human serum (5 mL of complement reference serum) was incubated in the presence of various doses of Efb (0.13-13 mmol/L) or in the presence of SdrG (13 or 20 mmol/L), at a final volume of 20 mL, at 37ЊC for 1 h, before a 1-h incubation at room temperature with antibody-coated sheep red blood cells (RBCs) (3 mL). Control high and low reference serum samples (5 mL) were incubated with 15 mL of PBS in the same fashion as were test serum samples, before incubations with antibodycoated sheep RBCs. After incubation, cells were centrifuged (800 g for 10 min), and the absorbance of the supernatants (150 mL) was measured at 405 nm by use of a microplate reader, as described above, to determine the percentage lysis of each sample. The data are expressed as percentage lysis of the standard reference serum, and the values were derived by use of the following equation: (absorbance of sample/absorbance of reference) ϫ CH50 value of reference (Diamedix).
Activation of the alternative pathway was measured by incubating the recombinant proteins Efb or SdrG (at the concentrations described above) with 10 mL of standard reference serum (Diamedix) for 1 h at 37ЊC. To each recombinant protein/serum mixture, 10 mL of gelatin-veronal buffer (GVB; Advanced Research Technologies) [35] , 10 mL of Mg Opsonophagocytic assay (OPA) and fluorescence-activated cell sorter (FACS) analysis. This method was based on previously reported techniques for evaluation of opsonophagocytic activity by use of antigen-coated fluorescent beads [36] [37] [38] [39] [40] [41] . Clumping factor A (ClfA) target antigen (Inhibitex) [42, 43] was coated on 1-mm diameter Fluoresbrite yellow green (YG) carboxylate microspheres (Polysciences), by use of the manufacturer's Carbodiimide Kit. Protein adsorption to the beads was verified by measuring the concentration of free protein remaining in the supernatant after antigen coupling, by use of a BCA total protein assay (Pierce). A human promyelocytic leukemia cell line (HL-60) [37] , cultured under conditions promoting granulocytic differentiation [38] , was used as the phagocytic effector cell (Flow Applications). The cell concentration was adjusted with Hank's balanced salt solution and 1% bovine serum albumin (OPA buffer). For each OPA, antigen- To determine the mechanism of Efb-mediated complement inactivation, the alternative complement-activity assay, in conjunction with flow cytometry, was performed to assess the deposition of C3b on the surface of rabbit RBCs. The alternative complement-activity assay was performed as described above, by use of 
RESULTS

Secretion of a C3-binding protein. To identify putative C3-binding proteins, whole-cell lysates from E. coli, S. carnosus, S.
aureus, or S. aureus supernatants were subjected to SDS-PAGE and were stained with Coomassie brilliant blue (figure 1A) or were transferred to a PVDF membrane and probed with digoxigenin-labeled C3b (figure 1B). A 19-kDa band from S. aureus was the most prominent C3b-binding component ( figure 1B) . Additional C3b-binding components, of lower molecular weight, which may represent degradation products of the 19-kDa protein, were also detected in these lanes. No C3b binding was detected in the lysates from E. coli or S. carnosus ( figure 1B) . C3b, which contains a hydrolyzed thioester bond, and not C3, was used as a probe, to demonstrate that binding to bacterial proteins was independent of the thioester conformation. Blots probed with digoxigenin-labeled C3 revealed similar staining, and blots probed with an AP-labeled secondary antibody alone revealed no color change after the addition of substrate (data not shown). All subsequent assays were performed with C3b or digoxigenin-labeled C3b.
Identification of the S. aureus C3-binding protein. The C3b-binding proteins identified by Western ligand blot analysis of whole S. aureus and S. aureus supernatants fractionated by SDS-PAGE were compared with protein bands of similar molecular weight identified on Coomassie brilliant blue-stained PVDF membranes supporting the same materials. Two candidate protein bands were selected from the stained PVDF membranes and submitted for N-terminal sequencing. The 2 candidate S. aureus C3b-binding proteins were identified as Efb (Entrez Protein accession number Q08691) [44] and SA1755 (Entrez Protein accession number E89983). Recombinant forms of Efb and SA1755, with N-terminal His-tags, were cloned, expressed, and purified (figure 2A). The binding of these proteins to C3b and fibrinogen was examined by use of Western ligand . Dose-dependent effect of extracellular fibrinogen-binding protein (Efb) on complement-mediated opsonophagocytosis.Determination of the MIC of Efb required for the inhibition of either the alternative or classical pathways was performed by testing Efb, at various doses (0.13-13 mmol/L), for complement-inhibitory activity. Staphylococcus epidermidis fibrinogen-binding protein (13 mmol/L) was used as a negative control and had no effect on complement-mediated lysis in either assay (data not shown). Spontaneous lysis for the alternative and classical assays was 18% and 19%, respectively, and is represented by the dashed line. Data are the percentage of lysis of red blood cells (RBCs) of the complement standard reference serum. blot ( figure 2B and 2C ). Recombinant forms of the secreted S. aureus protein Map19 and the S. epidermidis fibrinogen-binding protein (SdrG) were used as control recombinant proteins [12, 31] . Only Efb bound digoxigenin-labeled C3b and both Efb and SdrG, but neither SA1755 nor Map19 bound to digoxigeninlabeled fibrinogen ( figure 2B and 2C ). Membranes probed with only secondary antibody revealed no color change after the addition of substrate (data not shown).
C3b, fibrinogen, and human serum were subjected to SDS-PAGE and stained with Coomassie brilliant blue (figure 3A) or were transferred to PVDF membranes and probed with either recombinant Efb or anti-human C3 antibodies ( figure 3B and  3C) . The results of these experiments suggested that, when SDS-PAGE was performed under reducing conditions, Efb bound strongly to C3b but not to fibrinogen ( figure 3B ). The minor shift in molecular weight observed between the purified C3b achain and the C3 a-chain, detected in human serum (figure 3B and 3C), is due to the proteolytic removal of the 77-aa residue (C3a) from the amino terminus of the C3 a-chain, resulting in the formation of C3b. Blots probed with SA1755 and secondary antibody or with secondary antibody alone revealed no color change after the addition of substrate (data not shown).
An ELISA-type binding assay revealed a dose-dependent and saturable binding of Efb to C3b-coated microtiter wells, compared with SdrG ( figure 4) . Recombinant Efb exhibited saturation kinetics and bound C3b with an apparent K D of 0.6 ϫ 10 Ϫ7 mol/L. Neither SdrG (figure 4A) nor SA1755 (data not shown) bound to C3b-coated wells.
Interference of the classical and alternative complement pathways. To determine whether the binding of Efb to C3 could also affect C3 activity, we examined the effect of Efb in 2 functional assays, using lysis of RBCs as a readout for the classical and alternative pathways. Complement-mediated lysis of RBCs, as a function of either the classical or the alternative pathway, was inhibited if human serum was preincubated with Efb but not if it was incubated with control proteins ( figure  5A and 5B). Furthermore, Efb exhibited 180% complementinhibitory activity (classical and alternative pathways) over a broad range of concentrations (figure 6). The relatively low levels of Efb required to inhibit complement activity suggested that the complement-inhibitory properties of Efb may play a role in perpetuating S. aureus survival in vivo. SA1755 had no complement-inhibitory properties (data not shown).
Inhibition of complement-mediated opsonophagocytosis. An in vitro OPA was used to measure the effect of Efb on complement-mediated phagocytosis. This assay measured the phagocytic activity of HL-60 cells that were cultured under conditions designed to generate terminally differentiated granulocytes. Fluorescent beads coupled to a target antigen (ClfA) were opsonized with antigen-specific antibody (anti-ClfA) and complement. The opsonized particles were then incubated with the granulocytes, and the percentage of fluorescently labeled cells was used as a measure of phagocytic activity. Phagocytic activity was inhibited in a concentration-dependent manner by Efb, whereas the control protein SdrG (at any concentration) had no effect on phagocytosis (figure 7). At the highest concentration of Efb used (62 mg/mL), a significant reduction in phagocytic activity, from 52% to 24%, was observed. Control reactions containing complement only or monoclonal anti-ClfA antibodies only, in the absence of complement, resulted in 20% and 8% fluorescent cells, respectively ( figure 7) .
Analysis of cell-surface deposition of C3b. We have demonstrated that Efb preincubated with complement inhibited both the classical and the alternative pathways, on the basis of the RBC lysis assays. This inhibition of complement activity could be facilitated by a number of possible mechanisms: (1) Efb could block deposition of C3b on the cell surface/activator surface, (2) Efb could interfere with the assembly of the convertases, or (3) Efb could enzymatically degrade C3b. Efb did not appear to degrade C3, since C3 incubated in the presence of Efb did not result in any discernible degradation products, after examination by SDS-PAGE (data not shown). To further define the mechanism of Efb-mediated inhibition of complement activation, the deposition of C3b on the cell surface of RBCs was assessed by use of flow cytometry with FITC-conjugated polyclonal antibodies to C3, after the activation of the alternative pathway. Deposition of C3b on RBC surfaces was undetectable if human serum was preincubated with Efb (20 mmol/L) (figure 8A). Conversely, deposition of C3b on RBC surfaces was detectable if serum was preincubated in the presence of SdrG (20 mmol/L) (figure 8B) or left untreated ( figure  8C ). This experiment did not rule out, however, the possibility that Efb-bound C3 is unrecognizable by anti-C3 antibodies as a result of blocked antibody epitopes. This scenario is not likely, since anti-C3 antibodies used in an ELISA-type binding assay were not inhibited from binding plate-bound C3b in the presence of increasing concentrations of Efb (data not shown). The high signal intensity and the low number of cells staining positive for C3b can also be explained by the fact that the RBCs were examined by use of FACS analysis during conditions of continuous complement activation, and it is likely that many cells were lysed during the FACS analysis. These data suggest that Efb inhibits complement activity by preventing C3b from binding to activator surfaces.
DISCUSSION
S. aureus uses various immune-evasion strategies: protein A and Map can interfere with humoral [45] and memory T cell responses [12] , respectively, and super antigens (bacterial toxins) can nonspecifically activate up to 20% of naive T cells, resulting in the release of large quantities of cytokines, generating a clinical condition resembling septic shock [1] .
The present study has described another S. aureus microbial immunomodulatory molecule (Efb) that binds to C3 and interferes with complement activation and C3-mediated opsonization. A large number of human pathogens have evolved mechanisms of complement evasion [17, 46, 47] . However, the list of human pathogens that can generate proteins that directly or indirectly interact with C3 is limited and can be divided into 2 principal functional groups: (1) surface-expressed C3-binding proteins that promote pathogen internalization into host cells and (2) C3-binding proteins that interfere with complement function. For example, Mycobacterium leprae, Leishmania major, and Legionella pneumophila use C3 as a ligand to facilitate their internalization into mononuclear cells via complement receptors CR1 and CR3 [48] [49] [50] . Trypanosoma cruzi produce an anchored protein, gp160, that interferes with complement activation by binding C3b and inhibiting formation of C3 convertase [51] . Pseudomonas aeruginosa (alkaline protease) and herpes simplex virus type 1 and type 2 (glycoprotein gC-1 and -2) can all generate C3-binding proteins with complement-inhibitory properties, and they function by either degrading C3 or accelerating the decay of C3 convertases, respectively [52, 53] . Streptococcus pneumoniae, Chlamydia trachomatis, and Mycobacterium tuberculosis produce C3-binding proteins, but their complementinhibitory properties have not been defined [54] [55] [56] .
Efb is the first complement-regulatory microbial immunomodulatory molecule identified from S. aureus, and, in conjunction with other S. aureus immune-evasion mechanisms, may further explain the capacity of S. aureus to cause persistent infections. Efb is unique from other C3-binding proteins and represents a new functional group of proteins that involve preventing C3 activation by directly preventing its binding to activator surfaces.
Capsule formation by S. aureus appears to play a key role in the protection against complement-mediated phagocytosis. Previous studies have shown that encapsulated (CP + ) S. aureus strains have decreased phagocytic killing and are more virulent than strains of unencapsulated (CP Ϫ ) S. aureus [57] .
The diminished phagocytic susceptibility of CP + S. aureus was due, in part, to a decreased deposition of C3 fragments on the cell surface of S. aureus, in addition to the masking of surfacebound C3 by the capsule, resulting in diminished complement receptor-mediated recognition by neutrophils [24, 58, 59] . However, capsule production occurs primarily during the later stages of bacterial growth, compared with Efb, which is constitutively expressed [27, 59] . We hypothesize that the complement-inhibitory properties of Efb may serve to neutralize complement activation initiated by S. aureus during the early stages of infection, when capsule production has not been initiated. The following findings suggest that Efb may play an important role in S. aureus survival and virulence, at least, in part, by diminishing or preventing complement activation during infection: (1) the relatively low concentrations of Efb required to inhibit complement activation (3 mmol/L), (2) Efb's highly conserved nature among Efb + S. aureus strains [60] , and (3) the higher percentage of invasive isolates containing the efb determinant, compared with carriage isolates [61] .
Efb represents a novel member of a growing family of S. aureus immunomodulatory proteins. Efb had been previously characterized as a fibrinogen-binding protein [44] . The significance of dual binding to both C3 and fibrinogen by Efb needs to be further examined, although it is becoming clear that many microbial immunomodulatory proteins can also serve as adhesins. It is not unusual for bacterial proteins to have multiple biological activities [4, 10-12, 62, 63] , and these multifunctional proteins may contribute to the bacteria's ability to colonize, survive, and persist in vastly different environments (e.g., skin, blood, kidney, or bone) and cause a broad range of diseases. For example, the secreted S. aureus Map has been described as a microbial surface component recognizing adhesive matrix molecules [62, 64, 65] and as a microbial immunomodulatory molecule [4, 12, 62] , and the streptococcal M protein, which also binds fibrinogen, can also interfere with the alternative pathway, by mechanisms not clearly defined [63] .
The data presented here suggest that inhibition of complement activity by Efb is mediated by blocking deposition of C3 to activator surfaces. A more detailed investigation further defining the mechanism of complement inactivation by Efb and determining the role of Efb in vivo, by use of animal models of S. aureus infection, is ongoing.
